Product Description
VT-122 is the co-administration of the cyclo-oxygenase 2 (COX-2) inhibitor, etodolac and the beta-adrenergic antagonist, propranolol. It is proposed that these drugs can attenuate systemic inflammation and ameliorate the symptoms of inflammatory cachexia in patients with advanced cancer. As a result, this treatment may improve tolerability and adherence to anti-cancer therapy, thereby yielding direct and indirect benefits in reducing disease progression and improving both the life expectancy and quality of life for patients with advanced cancer. (Sourced from: https://www.clinicaltrials.gov/ct2/show/NCT01265576)
Mechanisms of Action: COX2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Vicus
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Wasting Syndrome|Cachexia|Hepatocellular Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| VT1-CAX-200 | P2 |
Unknown status |
Hepatocellular Carcinoma |
2014-02-01 |
2019-03-19 |
Treatments |
|
| VT-122 | P2 |
Completed |
Cachexia|Wasting Syndrome |
2008-08-01 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|